| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 18 | 2022 | 935 | 2.660 |
Why?
|
| Receptors, CXCR5 | 5 | 2019 | 15 | 2.080 |
Why?
|
| Chemokine CXCL13 | 6 | 2019 | 18 | 1.830 |
Why?
|
| Immunity, Mucosal | 11 | 2008 | 47 | 1.730 |
Why?
|
| Cell Movement | 17 | 2019 | 571 | 1.650 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 8 | 2014 | 42 | 1.640 |
Why?
|
| Chemokines, CC | 9 | 2014 | 51 | 1.630 |
Why?
|
| Chemokine CCL5 | 7 | 2018 | 39 | 1.260 |
Why?
|
| Streptococcus pneumoniae | 4 | 2014 | 30 | 1.230 |
Why?
|
| Bacterial Proteins | 7 | 2014 | 540 | 1.230 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2022 | 15 | 1.200 |
Why?
|
| Receptors, Chemokine | 10 | 2016 | 70 | 1.190 |
Why?
|
| Neoplasm Invasiveness | 9 | 2016 | 251 | 1.180 |
Why?
|
| Colitis | 5 | 2008 | 65 | 1.160 |
Why?
|
| Receptors, CCR | 6 | 2014 | 24 | 1.120 |
Why?
|
| Pneumococcal Infections | 4 | 2014 | 29 | 1.080 |
Why?
|
| Chemokines, CXC | 6 | 2016 | 35 | 0.970 |
Why?
|
| Epitopes, T-Lymphocyte | 5 | 2014 | 57 | 0.960 |
Why?
|
| Gene Regulatory Networks | 2 | 2021 | 120 | 0.900 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2019 | 807 | 0.870 |
Why?
|
| Cytokines | 12 | 2010 | 602 | 0.860 |
Why?
|
| Cell Line, Tumor | 23 | 2019 | 2231 | 0.840 |
Why?
|
| Entrepreneurship | 1 | 2021 | 5 | 0.820 |
Why?
|
| Biotechnology | 1 | 2021 | 15 | 0.810 |
Why?
|
| Adjuvants, Immunologic | 6 | 2004 | 107 | 0.810 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 626 | 0.770 |
Why?
|
| CD4-Positive T-Lymphocytes | 11 | 2010 | 259 | 0.760 |
Why?
|
| Metalloproteases | 3 | 2015 | 16 | 0.750 |
Why?
|
| Interferon-gamma | 6 | 2014 | 250 | 0.740 |
Why?
|
| Drug Delivery Systems | 4 | 2017 | 202 | 0.720 |
Why?
|
| Chemokines | 5 | 2011 | 97 | 0.690 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2015 | 88 | 0.680 |
Why?
|
| Mice | 26 | 2014 | 5913 | 0.670 |
Why?
|
| Receptors, CXCR4 | 3 | 2013 | 69 | 0.670 |
Why?
|
| Mycobacterium avium subsp. paratuberculosis | 2 | 2008 | 6 | 0.620 |
Why?
|
| Mice, Inbred BALB C | 9 | 2014 | 661 | 0.600 |
Why?
|
| Humans | 56 | 2023 | 37093 | 0.600 |
Why?
|
| Killer Cells, Natural | 2 | 2008 | 92 | 0.590 |
Why?
|
| Nasal Mucosa | 6 | 2004 | 29 | 0.580 |
Why?
|
| Prostate | 5 | 2016 | 154 | 0.580 |
Why?
|
| Epitopes | 2 | 2011 | 148 | 0.580 |
Why?
|
| Matrix Metalloproteinases | 4 | 2019 | 48 | 0.570 |
Why?
|
| Epitope Mapping | 2 | 2014 | 31 | 0.570 |
Why?
|
| Nanoparticles | 5 | 2020 | 318 | 0.570 |
Why?
|
| Apoptosis | 15 | 2020 | 1398 | 0.560 |
Why?
|
| Receptors, CXCR3 | 7 | 2016 | 31 | 0.560 |
Why?
|
| Animals | 32 | 2020 | 15081 | 0.530 |
Why?
|
| Signal Transduction | 7 | 2020 | 1908 | 0.520 |
Why?
|
| Female | 31 | 2023 | 20969 | 0.520 |
Why?
|
| Breast Neoplasms | 6 | 2023 | 1502 | 0.510 |
Why?
|
| Ovalbumin | 7 | 2004 | 47 | 0.500 |
Why?
|
| Ovarian Neoplasms | 3 | 2019 | 312 | 0.490 |
Why?
|
| Immunodominant Epitopes | 1 | 2014 | 27 | 0.480 |
Why?
|
| Th1 Cells | 6 | 2008 | 92 | 0.480 |
Why?
|
| Male | 23 | 2022 | 20025 | 0.470 |
Why?
|
| Interleukin-10 | 4 | 2010 | 75 | 0.470 |
Why?
|
| Peptides | 3 | 2017 | 320 | 0.470 |
Why?
|
| Cell Proliferation | 13 | 2020 | 1198 | 0.470 |
Why?
|
| Antibodies, Bacterial | 3 | 2008 | 109 | 0.460 |
Why?
|
| GTP-Binding Proteins | 1 | 2013 | 60 | 0.440 |
Why?
|
| Protein Subunits | 1 | 2013 | 87 | 0.440 |
Why?
|
| Cell Adhesion | 3 | 2016 | 212 | 0.430 |
Why?
|
| Prostatic Hyperplasia | 2 | 2009 | 34 | 0.430 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2020 | 222 | 0.420 |
Why?
|
| Immunoglobulin G | 8 | 2008 | 237 | 0.410 |
Why?
|
| Proteins | 3 | 2008 | 369 | 0.400 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2010 | 448 | 0.400 |
Why?
|
| RNA, Messenger | 8 | 2019 | 1207 | 0.390 |
Why?
|
| Focal Adhesion Kinase 1 | 2 | 2011 | 19 | 0.390 |
Why?
|
| Yersinia pestis | 4 | 1999 | 35 | 0.380 |
Why?
|
| Hemin | 3 | 1999 | 6 | 0.360 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2010 | 29 | 0.360 |
Why?
|
| Chemokine CXCL10 | 2 | 2008 | 37 | 0.360 |
Why?
|
| Mice, Knockout | 7 | 2011 | 933 | 0.360 |
Why?
|
| src-Family Kinases | 1 | 2010 | 46 | 0.360 |
Why?
|
| T-Lymphocytes | 3 | 2008 | 357 | 0.350 |
Why?
|
| Epithelial Cells | 5 | 2017 | 384 | 0.350 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 168 | 0.340 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2008 | 92 | 0.340 |
Why?
|
| Integrins | 1 | 2009 | 51 | 0.340 |
Why?
|
| Caspase 9 | 1 | 2009 | 30 | 0.330 |
Why?
|
| Mice, Inbred C57BL | 10 | 2011 | 1609 | 0.330 |
Why?
|
| Chlamydia Infections | 2 | 2008 | 196 | 0.330 |
Why?
|
| Neutrophils | 4 | 2008 | 131 | 0.330 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2009 | 55 | 0.330 |
Why?
|
| Antineoplastic Agents | 6 | 2019 | 803 | 0.330 |
Why?
|
| Immunoglobulin A | 6 | 2008 | 58 | 0.320 |
Why?
|
| Membrane Transport Proteins | 2 | 2009 | 95 | 0.320 |
Why?
|
| Technology, Pharmaceutical | 1 | 2008 | 27 | 0.320 |
Why?
|
| Lymphocyte Activation | 5 | 2014 | 236 | 0.320 |
Why?
|
| Receptors, CCR5 | 5 | 2018 | 61 | 0.320 |
Why?
|
| Antibodies | 2 | 2008 | 141 | 0.320 |
Why?
|
| Adenocarcinoma | 3 | 2014 | 251 | 0.310 |
Why?
|
| Caspase 3 | 1 | 2009 | 207 | 0.310 |
Why?
|
| Prognosis | 4 | 2022 | 739 | 0.310 |
Why?
|
| Chlamydia muridarum | 1 | 2008 | 104 | 0.300 |
Why?
|
| Paratuberculosis | 1 | 2007 | 4 | 0.300 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2017 | 623 | 0.290 |
Why?
|
| Taxoids | 2 | 2017 | 37 | 0.290 |
Why?
|
| Flow Cytometry | 6 | 2016 | 399 | 0.280 |
Why?
|
| Spleen | 4 | 2014 | 199 | 0.280 |
Why?
|
| Tumor Cells, Cultured | 5 | 2016 | 502 | 0.280 |
Why?
|
| Membrane Proteins | 4 | 2019 | 517 | 0.270 |
Why?
|
| Carrier State | 1 | 2006 | 29 | 0.270 |
Why?
|
| Protein Binding | 4 | 2014 | 972 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 182 | 0.270 |
Why?
|
| Receptors, Virus | 2 | 2016 | 21 | 0.260 |
Why?
|
| T-Lymphocyte Subsets | 5 | 2007 | 88 | 0.260 |
Why?
|
| Lipoproteins | 1 | 2005 | 64 | 0.250 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2004 | 20 | 0.240 |
Why?
|
| Immunity, Cellular | 5 | 2008 | 70 | 0.240 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2017 | 213 | 0.240 |
Why?
|
| Disease Progression | 3 | 2019 | 601 | 0.240 |
Why?
|
| Enterocolitis | 1 | 2003 | 2 | 0.230 |
Why?
|
| Adoptive Transfer | 1 | 2003 | 48 | 0.230 |
Why?
|
| Adaptation, Physiological | 1 | 2004 | 109 | 0.230 |
Why?
|
| Blotting, Western | 5 | 2017 | 859 | 0.230 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2002 | 16 | 0.220 |
Why?
|
| Amino Acid Sequence | 5 | 2014 | 1180 | 0.220 |
Why?
|
| Immunoenzyme Techniques | 3 | 2016 | 108 | 0.210 |
Why?
|
| Chemokines, C | 2 | 1999 | 2 | 0.210 |
Why?
|
| Molecular Sequence Data | 5 | 2014 | 1568 | 0.210 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2014 | 29 | 0.210 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2021 | 8 | 0.200 |
Why?
|
| Clinical Trials as Topic | 1 | 2023 | 204 | 0.200 |
Why?
|
| Disease Models, Animal | 4 | 2008 | 1371 | 0.200 |
Why?
|
| Salmonella typhimurium | 1 | 2001 | 40 | 0.200 |
Why?
|
| Physician-Patient Relations | 1 | 2022 | 128 | 0.200 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2008 | 356 | 0.200 |
Why?
|
| Antibody Formation | 3 | 2008 | 74 | 0.200 |
Why?
|
| Administration, Intranasal | 5 | 2002 | 79 | 0.190 |
Why?
|
| Recurrence | 1 | 2021 | 131 | 0.190 |
Why?
|
| Cluster Analysis | 2 | 2019 | 195 | 0.190 |
Why?
|
| Ligands | 3 | 2007 | 349 | 0.190 |
Why?
|
| Qualitative Research | 1 | 2023 | 446 | 0.190 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 358 | 0.180 |
Why?
|
| Neoplasm Metastasis | 4 | 2019 | 219 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 128 | 0.180 |
Why?
|
| Sialoglycoproteins | 2 | 1999 | 11 | 0.180 |
Why?
|
| Lymphokines | 2 | 1999 | 13 | 0.180 |
Why?
|
| Hedgehog Proteins | 1 | 2020 | 50 | 0.180 |
Why?
|
| Systems Theory | 1 | 2019 | 3 | 0.180 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 583 | 0.170 |
Why?
|
| Principal Component Analysis | 1 | 2019 | 89 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2007 | 55 | 0.170 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 219 | 0.170 |
Why?
|
| Receptors, Scavenger | 2 | 2016 | 15 | 0.170 |
Why?
|
| Plague | 1 | 1999 | 25 | 0.160 |
Why?
|
| Immunity | 1 | 1999 | 53 | 0.160 |
Why?
|
| Biological Products | 1 | 2020 | 71 | 0.160 |
Why?
|
| Cell Division | 3 | 2005 | 307 | 0.160 |
Why?
|
| GTPase-Activating Proteins | 2 | 2010 | 29 | 0.160 |
Why?
|
| Mutation | 6 | 2022 | 1095 | 0.160 |
Why?
|
| Drug Resistance, Multiple | 1 | 2018 | 27 | 0.160 |
Why?
|
| Aged | 5 | 2023 | 6741 | 0.160 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 2 | 2017 | 51 | 0.160 |
Why?
|
| Embryonic Stem Cells | 2 | 2008 | 59 | 0.150 |
Why?
|
| Liposomes | 2 | 2009 | 118 | 0.150 |
Why?
|
| Image Cytometry | 2 | 2007 | 7 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 494 | 0.150 |
Why?
|
| Dendritic Cells | 2 | 2008 | 113 | 0.150 |
Why?
|
| Cytoskeleton | 2 | 2016 | 110 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2017 | 21 | 0.150 |
Why?
|
| Clusterin | 1 | 2017 | 9 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2017 | 55 | 0.150 |
Why?
|
| Epithelium | 1 | 2017 | 79 | 0.140 |
Why?
|
| Interleukin-6 | 3 | 2009 | 153 | 0.140 |
Why?
|
| Stilbenes | 1 | 2017 | 44 | 0.140 |
Why?
|
| Receptors, CCR6 | 1 | 2016 | 3 | 0.140 |
Why?
|
| Serum Amyloid A Protein | 2 | 2008 | 14 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 111 | 0.140 |
Why?
|
| Curcumin | 1 | 2017 | 74 | 0.140 |
Why?
|
| Andrographis | 1 | 2016 | 4 | 0.140 |
Why?
|
| Receptors, CXCR | 1 | 2016 | 6 | 0.140 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2016 | 12 | 0.140 |
Why?
|
| Receptors, Androgen | 1 | 2017 | 126 | 0.130 |
Why?
|
| Middle Aged | 5 | 2023 | 10129 | 0.130 |
Why?
|
| Mice, Inbred Strains | 2 | 2010 | 116 | 0.130 |
Why?
|
| Treatment Outcome | 1 | 2019 | 1369 | 0.130 |
Why?
|
| Exosomes | 1 | 2017 | 101 | 0.130 |
Why?
|
| Nanostructures | 1 | 2017 | 134 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 2 | 2015 | 360 | 0.130 |
Why?
|
| Diterpenes | 1 | 2016 | 92 | 0.130 |
Why?
|
| Antigens, Bacterial | 2 | 2007 | 132 | 0.130 |
Why?
|
| Cytoskeletal Proteins | 1 | 2016 | 105 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2008 | 159 | 0.120 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 275 | 0.120 |
Why?
|
| HLA Antigens | 1 | 2014 | 20 | 0.120 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 110 | 0.120 |
Why?
|
| Interleukins | 1 | 2014 | 29 | 0.120 |
Why?
|
| Antibody Specificity | 2 | 2004 | 79 | 0.120 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 186 | 0.120 |
Why?
|
| Gene Expression Regulation | 3 | 2008 | 1015 | 0.120 |
Why?
|
| Coculture Techniques | 1 | 2014 | 101 | 0.120 |
Why?
|
| Lymph Nodes | 1 | 2014 | 67 | 0.120 |
Why?
|
| Gene Deletion | 2 | 2005 | 166 | 0.120 |
Why?
|
| Tissue Array Analysis | 2 | 2011 | 67 | 0.120 |
Why?
|
| Chemokine CXCL11 | 2 | 2016 | 7 | 0.120 |
Why?
|
| Protein Structure, Secondary | 1 | 2014 | 183 | 0.110 |
Why?
|
| Receptor, PAR-1 | 1 | 2013 | 10 | 0.110 |
Why?
|
| Thrombin | 1 | 2013 | 25 | 0.110 |
Why?
|
| Intestinal Mucosa | 2 | 2007 | 122 | 0.110 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2013 | 30 | 0.110 |
Why?
|
| Antigens, CD | 2 | 2004 | 121 | 0.110 |
Why?
|
| Up-Regulation | 3 | 2005 | 513 | 0.110 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 893 | 0.110 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2013 | 46 | 0.110 |
Why?
|
| Protein Isoforms | 1 | 2013 | 130 | 0.110 |
Why?
|
| Cells, Cultured | 3 | 2006 | 1518 | 0.110 |
Why?
|
| Nanotechnology | 2 | 2017 | 153 | 0.110 |
Why?
|
| Cell Survival | 4 | 2018 | 864 | 0.110 |
Why?
|
| United States | 1 | 2022 | 4223 | 0.100 |
Why?
|
| Th2 Cells | 3 | 2001 | 58 | 0.100 |
Why?
|
| Proteomics | 3 | 2022 | 325 | 0.100 |
Why?
|
| Mice, SCID | 2 | 2009 | 150 | 0.100 |
Why?
|
| Smoke | 1 | 2011 | 40 | 0.100 |
Why?
|
| Cell Separation | 2 | 2008 | 93 | 0.100 |
Why?
|
| B-Lymphocytes | 2 | 2004 | 185 | 0.100 |
Why?
|
| Cisplatin | 1 | 2011 | 72 | 0.090 |
Why?
|
| Mice, Transgenic | 2 | 2004 | 617 | 0.090 |
Why?
|
| Chemokine CXCL5 | 1 | 2010 | 5 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 98 | 0.090 |
Why?
|
| Models, Molecular | 1 | 2014 | 808 | 0.090 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2010 | 9 | 0.090 |
Why?
|
| Histocompatibility Antigens | 1 | 2010 | 13 | 0.090 |
Why?
|
| Binding, Competitive | 1 | 2010 | 111 | 0.090 |
Why?
|
| Interleukin-12 | 2 | 2001 | 47 | 0.090 |
Why?
|
| Neoplasms | 2 | 2011 | 1103 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 935 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 1039 | 0.090 |
Why?
|
| Models, Biological | 1 | 2013 | 677 | 0.090 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2009 | 12 | 0.080 |
Why?
|
| Stromal Cells | 1 | 2009 | 49 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 161 | 0.080 |
Why?
|
| Dendrimers | 1 | 2009 | 13 | 0.080 |
Why?
|
| Antigens, CD34 | 1 | 2009 | 19 | 0.080 |
Why?
|
| Enzyme Activation | 1 | 2010 | 444 | 0.080 |
Why?
|
| Micelles | 1 | 2009 | 32 | 0.080 |
Why?
|
| DNA Damage | 1 | 2011 | 352 | 0.080 |
Why?
|
| Absorption | 1 | 2008 | 25 | 0.080 |
Why?
|
| Hydrogels | 1 | 2009 | 37 | 0.080 |
Why?
|
| Quantum Dots | 1 | 2009 | 30 | 0.080 |
Why?
|
| Bone and Bones | 1 | 2009 | 86 | 0.080 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2008 | 5 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 1 | 2009 | 118 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2009 | 106 | 0.080 |
Why?
|
| Bacterial Outer Membrane Proteins | 2 | 1999 | 52 | 0.080 |
Why?
|
| Drug Stability | 1 | 2008 | 116 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2009 | 259 | 0.080 |
Why?
|
| Biocompatible Materials | 1 | 2008 | 76 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2008 | 224 | 0.080 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2007 | 43 | 0.080 |
Why?
|
| Particle Size | 1 | 2008 | 215 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2011 | 277 | 0.080 |
Why?
|
| Drug Synergism | 2 | 2019 | 177 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2008 | 59 | 0.080 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2007 | 20 | 0.070 |
Why?
|
| Amyloid Precursor Protein Secretases | 2 | 2019 | 33 | 0.070 |
Why?
|
| Cytoplasm | 1 | 2007 | 143 | 0.070 |
Why?
|
| Drug Carriers | 1 | 2008 | 125 | 0.070 |
Why?
|
| Polymers | 1 | 2008 | 121 | 0.070 |
Why?
|
| Immunoglobulin A, Secretory | 2 | 2004 | 16 | 0.070 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 123 | 0.070 |
Why?
|
| ADP-Ribosylation Factors | 1 | 2006 | 12 | 0.070 |
Why?
|
| Intracellular Membranes | 1 | 2006 | 38 | 0.070 |
Why?
|
| Membrane Glycoproteins | 2 | 2005 | 211 | 0.070 |
Why?
|
| Plasmodium yoelii | 1 | 2005 | 10 | 0.070 |
Why?
|
| Dermatitis | 1 | 2005 | 10 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2007 | 366 | 0.070 |
Why?
|
| Cerebellum | 1 | 2005 | 73 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 767 | 0.070 |
Why?
|
| Infertility, Female | 1 | 2005 | 24 | 0.070 |
Why?
|
| Genital Diseases, Female | 1 | 2005 | 37 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2011 | 938 | 0.060 |
Why?
|
| Adult | 4 | 2023 | 11712 | 0.060 |
Why?
|
| Gene Products, nef | 1 | 2005 | 19 | 0.060 |
Why?
|
| Chemokine CCL1 | 1 | 2004 | 2 | 0.060 |
Why?
|
| Adhesins, Bacterial | 1 | 2005 | 20 | 0.060 |
Why?
|
| Chlamydia trachomatis | 1 | 2005 | 68 | 0.060 |
Why?
|
| Chemokine CXCL6 | 1 | 2004 | 2 | 0.060 |
Why?
|
| Plant Extracts | 2 | 2020 | 286 | 0.060 |
Why?
|
| Malaria | 1 | 2005 | 78 | 0.060 |
Why?
|
| Chemokine CXCL12 | 1 | 2004 | 29 | 0.060 |
Why?
|
| Antigens, Surface | 1 | 2004 | 43 | 0.060 |
Why?
|
| Peptide Hormones | 1 | 2004 | 20 | 0.060 |
Why?
|
| Skin | 1 | 2005 | 174 | 0.060 |
Why?
|
| Leukocytes | 1 | 2004 | 72 | 0.060 |
Why?
|
| Cell Cycle Proteins | 2 | 2017 | 229 | 0.060 |
Why?
|
| Species Specificity | 1 | 2004 | 245 | 0.060 |
Why?
|
| Transcription, Genetic | 2 | 2004 | 578 | 0.060 |
Why?
|
| Reaction Time | 1 | 2004 | 143 | 0.060 |
Why?
|
| Malaria, Cerebral | 1 | 2004 | 31 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2004 | 149 | 0.060 |
Why?
|
| Immunization, Passive | 1 | 2003 | 19 | 0.060 |
Why?
|
| Immune Sera | 1 | 2003 | 59 | 0.060 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2004 | 86 | 0.060 |
Why?
|
| Inflammation | 2 | 2005 | 618 | 0.060 |
Why?
|
| Injections, Intraperitoneal | 1 | 2003 | 60 | 0.060 |
Why?
|
| Apolipoproteins | 1 | 2003 | 22 | 0.060 |
Why?
|
| Leptin | 1 | 2004 | 118 | 0.050 |
Why?
|
| Rabbits | 1 | 2003 | 283 | 0.050 |
Why?
|
| Crohn Disease | 1 | 2003 | 63 | 0.050 |
Why?
|
| Feces | 1 | 2003 | 111 | 0.050 |
Why?
|
| Chemokine CCL3 | 1 | 2002 | 14 | 0.050 |
Why?
|
| Chemokine CCL4 | 1 | 2002 | 19 | 0.050 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2002 | 16 | 0.050 |
Why?
|
| Hela Cells | 2 | 2006 | 366 | 0.050 |
Why?
|
| Patient Participation | 1 | 2023 | 75 | 0.050 |
Why?
|
| Weight Loss | 1 | 2003 | 131 | 0.050 |
Why?
|
| Defensins | 2 | 1999 | 5 | 0.050 |
Why?
|
| Monocytes | 1 | 2004 | 257 | 0.050 |
Why?
|
| Peyer's Patches | 1 | 2001 | 16 | 0.050 |
Why?
|
| Focus Groups | 1 | 2023 | 348 | 0.050 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2021 | 62 | 0.050 |
Why?
|
| Restriction Mapping | 2 | 1999 | 45 | 0.050 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2001 | 1 | 0.050 |
Why?
|
| Chromosome Aberrations | 1 | 2021 | 60 | 0.050 |
Why?
|
| Antibody-Producing Cells | 1 | 2001 | 6 | 0.050 |
Why?
|
| Interphase | 1 | 2001 | 6 | 0.050 |
Why?
|
| Receptors, Interleukin | 1 | 2001 | 11 | 0.050 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2001 | 15 | 0.050 |
Why?
|
| Base Sequence | 3 | 1999 | 997 | 0.050 |
Why?
|
| Decision Making | 1 | 2023 | 203 | 0.050 |
Why?
|
| Temperature | 2 | 1999 | 286 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2001 | 82 | 0.050 |
Why?
|
| Nuclear Proteins | 2 | 2016 | 307 | 0.050 |
Why?
|
| Receptors, Cell Surface | 2 | 2005 | 144 | 0.050 |
Why?
|
| Phenotype | 2 | 1999 | 689 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2005 | 441 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1999 | 24 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2014 | 1130 | 0.040 |
Why?
|
| Genes, Bacterial | 1 | 1999 | 90 | 0.040 |
Why?
|
| Lethal Dose 50 | 1 | 1999 | 30 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 1999 | 474 | 0.040 |
Why?
|
| Iron Chelating Agents | 1 | 1999 | 21 | 0.040 |
Why?
|
| alpha-Defensins | 1 | 1999 | 17 | 0.040 |
Why?
|
| Bacterial Adhesion | 1 | 1999 | 37 | 0.040 |
Why?
|
| Superoxides | 1 | 1999 | 53 | 0.040 |
Why?
|
| Chlorides | 1 | 1999 | 56 | 0.040 |
Why?
|
| Immunization | 1 | 1999 | 92 | 0.040 |
Why?
|
| Ferric Compounds | 1 | 1999 | 51 | 0.040 |
Why?
|
| Octamer Transcription Factor-3 | 2 | 2008 | 19 | 0.040 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 1999 | 149 | 0.040 |
Why?
|
| Ovary | 1 | 2019 | 108 | 0.040 |
Why?
|
| Virulence | 1 | 1999 | 223 | 0.040 |
Why?
|
| Folic Acid | 1 | 2018 | 46 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 1999 | 190 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1997 | 16 | 0.040 |
Why?
|
| Microscopy, Confocal | 2 | 2008 | 218 | 0.040 |
Why?
|
| Pigmentation | 1 | 1997 | 11 | 0.040 |
Why?
|
| Operon | 1 | 1997 | 44 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 290 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 1999 | 220 | 0.040 |
Why?
|
| Caco-2 Cells | 1 | 2017 | 52 | 0.040 |
Why?
|
| Kinetics | 1 | 1999 | 708 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 2379 | 0.040 |
Why?
|
| Immunoblotting | 1 | 2017 | 176 | 0.040 |
Why?
|
| Surface Properties | 1 | 2017 | 130 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 84 | 0.040 |
Why?
|
| Chemokine CCL20 | 1 | 2016 | 7 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2023 | 864 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 1999 | 316 | 0.030 |
Why?
|
| Androgens | 1 | 2017 | 89 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2019 | 339 | 0.030 |
Why?
|
| Cyclin B1 | 1 | 2016 | 16 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2017 | 252 | 0.030 |
Why?
|
| CDC2 Protein Kinase | 1 | 2016 | 17 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 1999 | 461 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2016 | 27 | 0.030 |
Why?
|
| Cyclins | 1 | 2016 | 37 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 2016 | 27 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2017 | 147 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 31 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2017 | 191 | 0.030 |
Why?
|
| Escherichia coli | 1 | 1999 | 453 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2015 | 41 | 0.030 |
Why?
|
| Siderophores | 1 | 1995 | 9 | 0.030 |
Why?
|
| ADAM Proteins | 1 | 2015 | 16 | 0.030 |
Why?
|
| Receptors, CCR3 | 2 | 2005 | 10 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 132 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 1997 | 515 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 173 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2005 | 306 | 0.030 |
Why?
|
| Histones | 1 | 2016 | 190 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 1354 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 628 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2016 | 928 | 0.030 |
Why?
|
| Risk Factors | 2 | 2011 | 3562 | 0.030 |
Why?
|
| Cell Transformation, Viral | 1 | 2011 | 29 | 0.020 |
Why?
|
| Receptor Cross-Talk | 1 | 2011 | 17 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2011 | 25 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2011 | 21 | 0.020 |
Why?
|
| Deoxyguanosine | 1 | 2011 | 35 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 91 | 0.020 |
Why?
|
| Human papillomavirus 16 | 1 | 2011 | 35 | 0.020 |
Why?
|
| Receptors, Interleukin-10 | 1 | 2010 | 4 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2017 | 642 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2010 | 24 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2010 | 85 | 0.020 |
Why?
|
| DNA Repair | 1 | 2011 | 188 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 326 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2010 | 93 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 269 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2008 | 81 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2007 | 37 | 0.020 |
Why?
|
| Granulocytes | 1 | 2007 | 29 | 0.020 |
Why?
|
| Cell Size | 1 | 2007 | 44 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 923 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2011 | 336 | 0.020 |
Why?
|
| Aluminum Compounds | 1 | 2006 | 8 | 0.020 |
Why?
|
| Phosphatidylinositol 4,5-Diphosphate | 1 | 2006 | 6 | 0.020 |
Why?
|
| Fluorides | 1 | 2006 | 19 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2006 | 68 | 0.020 |
Why?
|
| Membrane Microdomains | 1 | 2006 | 47 | 0.020 |
Why?
|
| Receptors, CCR1 | 1 | 2005 | 8 | 0.020 |
Why?
|
| Chemokine CCL11 | 1 | 2005 | 1 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2006 | 132 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 181 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2005 | 80 | 0.020 |
Why?
|
| Protein Transport | 1 | 2007 | 302 | 0.020 |
Why?
|
| Fallopian Tubes | 1 | 2005 | 17 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2005 | 45 | 0.020 |
Why?
|
| Actins | 1 | 2006 | 148 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 4268 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2005 | 51 | 0.020 |
Why?
|
| DNA Primers | 1 | 2005 | 286 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2005 | 37 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 90 | 0.020 |
Why?
|
| Receptors, Ghrelin | 1 | 2004 | 1 | 0.020 |
Why?
|
| Receptors, Leptin | 1 | 2004 | 13 | 0.020 |
Why?
|
| Ghrelin | 1 | 2004 | 13 | 0.020 |
Why?
|
| Human Growth Hormone | 1 | 2004 | 20 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2005 | 272 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2006 | 381 | 0.010 |
Why?
|
| Gene Expression | 1 | 2005 | 674 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 484 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 1742 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2004 | 1418 | 0.010 |
Why?
|
| Tetanus Toxoid | 1 | 1999 | 2 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1999 | 93 | 0.010 |
Why?
|
| HIV-1 | 1 | 2005 | 706 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1999 | 265 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1999 | 133 | 0.010 |
Why?
|
| Plasmids | 1 | 1999 | 246 | 0.010 |
Why?
|
| Vaccines | 1 | 1999 | 55 | 0.010 |
Why?
|
| Brain | 1 | 2004 | 1346 | 0.010 |
Why?
|
| Child | 1 | 2004 | 3131 | 0.010 |
Why?
|
| Bacteriocins | 1 | 1995 | 7 | 0.010 |
Why?
|